Skip to main content

RGNX

Stock

RGNX

Stock
Health Care
Biotechnology

Performance overview

RGNX Price
Price Chart

Forward-looking statistics

Beta
1.76
Risk
68.39%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Company info

SectorHealth Care
IndustryBiotechnology
Employees376
Market cap$693.5M

Fundamentals

Enterprise value$277.5M
Revenue$156.7M
Revenue per employee
Profit margin-100.62%
Debt to equity48.70

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.09
Dividend per share
Revenue per share$3.08
Avg trading volume (30 day)$9M
Avg trading volume (10 day)$8M
Put-call ratio

Macro factor sensitivity

Growth+3.5
Credit+7.1
Liquidity-1.1
Inflation-0.3
Commodities-0.3
Interest Rates-2.7

Valuation

Dividend yield0.00%
PEG Ratio-8.09
Price to sales2.81
P/E Ratio-8.09
Enterprise Value to Revenue1.77
Price to book1.60

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

RegenXBio Inc. RGNX revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.

Benzinga (June 5, 2025)
Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates

Regenxbio (RGNX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to loss of $1.38 per share a year ago.

Zacks Investment Research (May 12, 2025)
Jim Cramer lists his top 10 stocks that have jumped this week

'Mad Money' host Jim Cramer looks at the stocks that have jumped this week as the bull market continues to run.

CNBC Television (February 9, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free